David M. Dohan Ehrenfest
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
David M. Dohan Ehrenfest has a total of 70 co-authors. Here are the top co-authors by number of shared publications:
Gilberto Sammartino
Department of Oral Surgery, Faculty of Medicine, University of Naples Federico II, Naples, Italy
7 shared publications- Marco Del Corso
Private practice, Turin, Italy
6 shared publications - Lydia Vazquez
Department of Orofacial Rehabilitation, University Clinics of Dental Medicine (CUMD), University of Geneva, 1211 Geneva, Switzerland
4 shared publications Pierre Doglioli
3 shared publicationsTomas Albrektsson
Professor and head of the Department of Biomaterials, Institute for Clinical Sciences, The Sahlgrenska Academy at University of Gothenburg, Sweden
3 shared publicationsAdriano Piattelli
Department of Medical, Oral and Biotechnological Sciences, G. D'Annunzio University of Chieti-Pescara, Chieti, Italy
2 shared publications
Latest Publications
- Open Access
- 4 December 2019
- Published by Hindawi Limited in BioMed Research International
- Vol. 2019, 1-2
New Biomaterials and Regenerative Medicine Strategies in Periodontology, Oral Surgery, Esthetic and Implant Dentistry 2018
- 4 December 2019
- Published by Hindawi Limited in BioMed Research International
- Vol. 2019, 1-2
Open AccessNew Biomaterials and Regenerative Medicine Strategies in Periodontology, Oral Surgery, Esthetic and Implant Dentistry 2018
- Top Cited Papers
- 1 January 2019
- Published by Edra SpA in Muscles, Ligaments and Tendons Journal
- Vol. 04 (01) , 03-9
Classification of platelet concentrates (Platelet-Rich Plasma-PRP, Platelet-Rich Fibrin-PRF) for topical and infiltrative use in orthopedic and sports medicine: current consensus, clinical implications and perspectives
Platelet concentrates for topical and infiltrative use - commonly termed Platetet-Rich Plasma (PRP) or Platelet-Rich Fibrin (PRF) - are used or tested as surgical adjuvants or regenerative medicine preparations in most medical fields, particularly in sports medicine and orthopaedic surgery. Even if these products offer interesting therapeutic perspectives, their clinical relevance is largely debated, as the literature on the topic is often confused and contradictory. The long history of these products was always associated with confusions, mostly related to the lack of consensual terminology, characterization and classification of the many products that were tested in the last 40 years. The current consensus is based on a simple classification system dividing the many products in 4 main families, based on their fibrin architecture and cell content: Pure Platelet-Rich Plasma (P-PRP), such as the PRGF-Endoret technique; Leukocyte- and Platelet-Rich Plasma (LPRP), such as Biomet GPS system; Pure Platelet-Rich Fibrin (P-PRF), such as Fibrinet; Leukocyte- and Platelet-Rich Fibrin (L-PRF), such as Intra-Spin L-PRF. The 4 main families of products present different biological signatures and mechanisms, and obvious differences for clinical applications. This classification serves as a basis for further investigations of the effects of these products. Perspectives of evolutions of this classification and terminology are also discussed, particularly concerning the impact of the cell content, preservation and activation on these products in sports medicine and orthopaedics.
- 1 January 2019
- Published by Edra SpA in Muscles, Ligaments and Tendons Journal
- Vol. 04 (01) , 03-9
Top Cited PapersClassification of platelet concentrates (Platelet-Rich Plasma-PRP, Platelet-Rich Fibrin-PRF) for topical and infiltrative use in orthopedic and sports medicine: current consensus, clinical implications and perspectives
Platelet concentrates for topical and infiltrative use - commonly termed Platetet-Rich Plasma (PRP) or Platelet-Rich Fibrin (PRF) - are used or tested as surgical adjuvants or regenerative medicine preparations in most medical fields, particularly in sports medicine and orthopaedic surgery. Even if these products offer interesting therapeutic perspectives, their clinical relevance is largely debated, as the literature on the topic is often confused and contradictory. The long history of these products was always associated with confusions, mostly related to the lack of consensual terminology, characterization and classification of the many products that were tested in the last 40 years. The current consensus is based on a simple classification system dividing the many products in 4 main families, based on their fibrin architecture and cell content: Pure Platelet-Rich Plasma (P-PRP), such as the PRGF-Endoret technique; Leukocyte- and Platelet-Rich Plasma (LPRP), such as Biomet GPS system; Pure Platelet-Rich Fibrin (P-PRF), such as Fibrinet; Leukocyte- and Platelet-Rich Fibrin (L-PRF), such as Intra-Spin L-PRF. The 4 main families of products present different biological signatures and mechanisms, and obvious differences for clinical applications. This classification serves as a basis for further investigations of the effects of these products. Perspectives of evolutions of this classification and terminology are also discussed, particularly concerning the impact of the cell content, preservation and activation on these products in sports medicine and orthopaedics.
- Open Access
- 4 July 2017
- Published by Taylor & Francis in Platelets
- Vol. 29 (5) , 468-475
Leucocyte- and platelet-rich fibrin (L-PRF) as a regenerative medicine strategy for the treatment of refractory leg ulcers: a prospective cohort study
Chronic wounds (VLU: venous leg ulcer, DFU: diabetic foot ulcer, PU: pressure ulcer, or complex wounds) affect a significant proportion of the population. Despite appropriate standard wound care, such ulcers unfortunately may remain open for months or even years. The use of leukocyte- and platelet-rich fibrin (L-PRF) to cure skin ulcers is a simple and inexpensive method, widely used in some countries but unknown or neglected in most others. This auto-controlled prospective cohort study explored and quantified accurately for the first time the adjunctive benefits of topical applications of L-PRF in the management of such refractory ulcers in a diverse group of patients. Forty-four consecutive patients with VLUs (n = 28, 32 wounds: 17 ≤ 10 cm2 and 15 > 10 cm2), DPUs (n = 9, 10 wounds), PUs (n = 5), or complex wounds (n = 2), all refractory to standard treatment for ≥3 months, received a weekly application of L-PRF membranes. L-PRF was prepared following the original L-PRF method developed more than 15 years ago (400g, 12 minutes) using the Intra-Spin L-PRF centrifuge/system and the XPression box kit (Intra-Lock, Boca Raton, FL, USA; the only CE/FDA cleared system for the preparation of L-PRF). Changes in wound area were recorded longitudinally via digital planimetry. Adverse events and pain levels were also registered. All wounds showed significant improvements after the L-PRF therapy. All VLUs ≤ 10 cm2, all DFUs, as well as the two complex wounds showed full closure within a 3-month period. All wounds of patients with VLUs > 10 cm2 who continued therapy (10 wounds) could be closed, whereas in the five patients who discontinued therapy improvement of wound size was observed. Two out of the five PUs were closed, with improvement in the remaining three patients who again interrupted therapy (surface evolution from 7.35 ± 4.31 cm2 to 5.78 ± 3.81 cm2). No adverse events were observed. A topical application of L-PRF on chronic ulcers, recalcitrant to standard wound care, promotes healing and wound closure in all patients following the treatment. This new therapy is simple, safe and inexpensive, and should be considered a relevant therapeutic option for all refractory skin ulcers.
- 4 July 2017
- Published by Taylor & Francis in Platelets
- Vol. 29 (5) , 468-475
Open AccessLeucocyte- and platelet-rich fibrin (L-PRF) as a regenerative medicine strategy for the treatment of refractory leg ulcers: a prospective cohort study
Chronic wounds (VLU: venous leg ulcer, DFU: diabetic foot ulcer, PU: pressure ulcer, or complex wounds) affect a significant proportion of the population. Despite appropriate standard wound care, such ulcers unfortunately may remain open for months or even years. The use of leukocyte- and platelet-rich fibrin (L-PRF) to cure skin ulcers is a simple and inexpensive method, widely used in some countries but unknown or neglected in most others. This auto-controlled prospective cohort study explored and quantified accurately for the first time the adjunctive benefits of topical applications of L-PRF in the management of such refractory ulcers in a diverse group of patients. Forty-four consecutive patients with VLUs (n = 28, 32 wounds: 17 ≤ 10 cm2 and 15 > 10 cm2), DPUs (n = 9, 10 wounds), PUs (n = 5), or complex wounds (n = 2), all refractory to standard treatment for ≥3 months, received a weekly application of L-PRF membranes. L-PRF was prepared following the original L-PRF method developed more than 15 years ago (400g, 12 minutes) using the Intra-Spin L-PRF centrifuge/system and the XPression box kit (Intra-Lock, Boca Raton, FL, USA; the only CE/FDA cleared system for the preparation of L-PRF). Changes in wound area were recorded longitudinally via digital planimetry. Adverse events and pain levels were also registered. All wounds showed significant improvements after the L-PRF therapy. All VLUs ≤ 10 cm2, all DFUs, as well as the two complex wounds showed full closure within a 3-month period. All wounds of patients with VLUs > 10 cm2 who continued therapy (10 wounds) could be closed, whereas in the five patients who discontinued therapy improvement of wound size was observed. Two out of the five PUs were closed, with improvement in the remaining three patients who again interrupted therapy (surface evolution from 7.35 ± 4.31 cm2 to 5.78 ± 3.81 cm2). No adverse events were observed. A topical application of L-PRF on chronic ulcers, recalcitrant to standard wound care, promotes healing and wound closure in all patients following the treatment. This new therapy is simple, safe and inexpensive, and should be considered a relevant therapeutic option for all refractory skin ulcers.
- Open Access
- 22 January 2017
- Published by Wiley in BioMed Research International
- Vol. 2017, 1-3
New Biomaterials and Regenerative Medicine Strategies in Periodontology, Oral Surgery, Esthetic and Implant Dentistry 2016
- 22 January 2017
- Published by Wiley in BioMed Research International
- Vol. 2017, 1-3
Open AccessNew Biomaterials and Regenerative Medicine Strategies in Periodontology, Oral Surgery, Esthetic and Implant Dentistry 2016
- Open Access
- 17 March 2016
- Published by Hindawi Limited in BioMed Research International
- Vol. 2016, 1-3
Tissue Engineering and Dental Implantology: Biomaterials, New Technologies, and Stem Cells
- 17 March 2016
- Published by Hindawi Limited in BioMed Research International
- Vol. 2016, 1-3
Open AccessTissue Engineering and Dental Implantology: Biomaterials, New Technologies, and Stem Cells
- Open Access
- 1 January 2015
- Published by Wiley in BioMed Research International
- Vol. 2015, 1-3
New Biomaterials and Regenerative Medicine Strategies in Periodontology, Oral Surgery, Esthetic and Implant Dentistry
- 1 January 2015
- Published by Wiley in BioMed Research International
- Vol. 2015, 1-3
Open AccessNew Biomaterials and Regenerative Medicine Strategies in Periodontology, Oral Surgery, Esthetic and Implant Dentistry
- 1 August 2012
- Published by American Academy of Implant Dentistry in Journal of Oral Implantology
- Vol. 38 (4) , 309-310
Impact Factors in Scientific Journals: Keeping a Balance for the JOI Readers
Article Citation: James L. Rutkowski, Sheldon Winkler, Robert J. Buhite, Sebastiano Andreana, H. Dexter Barber, Nicholas Caplanis, Dennis Flanagan, John Kern, Jaime Lozada, Craig M. Misch, Harold F. Morris, Nicholas Radio, James Ference, David M. Dohan Ehrenfest, Omar Bayati, Barry Bartee, Kim Gowey, Richard Guaccio, Brian Jackson, Ahmad Kutkut, Pankaj Narkhede, John Nase, and Lidia M. Dohan Ehrenfest (2012) Impact Factors in Scientific Journals: Keeping a Balance for the JOI Readers. Journal of Oral Implantology: August 2012, Vol. 38, No. 4, pp. 309-310. doi: http://dx.doi.org/10.1563/AAID-JOI-D-12-Editorial.3804
- 1 August 2012
- Published by American Academy of Implant Dentistry in Journal of Oral Implantology
- Vol. 38 (4) , 309-310
Impact Factors in Scientific Journals: Keeping a Balance for the JOI Readers
Article Citation: James L. Rutkowski, Sheldon Winkler, Robert J. Buhite, Sebastiano Andreana, H. Dexter Barber, Nicholas Caplanis, Dennis Flanagan, John Kern, Jaime Lozada, Craig M. Misch, Harold F. Morris, Nicholas Radio, James Ference, David M. Dohan Ehrenfest, Omar Bayati, Barry Bartee, Kim Gowey, Richard Guaccio, Brian Jackson, Ahmad Kutkut, Pankaj Narkhede, John Nase, and Lidia M. Dohan Ehrenfest (2012) Impact Factors in Scientific Journals: Keeping a Balance for the JOI Readers. Journal of Oral Implantology: August 2012, Vol. 38, No. 4, pp. 309-310. doi: http://dx.doi.org/10.1563/AAID-JOI-D-12-Editorial.3804
- 1 April 2012
- Published by American Academy of Implant Dentistry in Journal of Oral Implantology
- Vol. 38 (2) , 181-187
The Use of Leukocyte- and Platelet-Rich Fibrin During Immediate Postextractive Implantation and Loading for the Esthetic Replacement of a Fractured Maxillary Central Incisor
Article Citation: Marco Del Corso, Ziv Mazor, James L. Rutkowski, David M. Dohan Ehrenfest, (2012) The Use of Leukocyte- and Platelet-Rich Fibrin During Immediate Postextractive Implantation and Loading for the Esthetic Replacement of a Fractured Maxillary Central Incisor. Journal of Oral Implantology: April 2012, Vol. 38, No. 2, pp. 181-187. doi: http://dx.doi.org/10.1563/AAID-JOI-D-12-CL.3802
- 1 April 2012
- Published by American Academy of Implant Dentistry in Journal of Oral Implantology
- Vol. 38 (2) , 181-187
The Use of Leukocyte- and Platelet-Rich Fibrin During Immediate Postextractive Implantation and Loading for the Esthetic Replacement of a Fractured Maxillary Central Incisor
Article Citation: Marco Del Corso, Ziv Mazor, James L. Rutkowski, David M. Dohan Ehrenfest, (2012) The Use of Leukocyte- and Platelet-Rich Fibrin During Immediate Postextractive Implantation and Loading for the Esthetic Replacement of a Fractured Maxillary Central Incisor. Journal of Oral Implantology: April 2012, Vol. 38, No. 2, pp. 181-187. doi: http://dx.doi.org/10.1563/AAID-JOI-D-12-CL.3802
- 22 March 2012
- Published by Wiley in Clinical Implant Dentistry and Related Research
- Vol. 14 (2) , 170-183
The Peri‐Implantitis: Implant Surfaces, Microstructure, and Physicochemical Aspects
There are two ways of looking at secondary failures of osseointegration; one is to reflect on possible causes for the failure, the other focuses on the pathology per se. In the first case, background factors such as mechanical trauma (adverse loading) or inflammations/infections are being discussed as the cause of failure. Then peri‐implantitis is a term reserved for implant disturbance due to inflammation/infections only. However, irrespective of the original reason for the failure being adverse loading or inflammation/infection, the end result with bone resorption and inflammation may be very similar. Hence, in the present article, an alternative outlook has been chosen. Trigerring factors for peri‐implantitis are generally gathered under four categories: lesions of peri‐implant attachment, presence of aggressive bacteria, excessive mechanical stress, and corrosion. If only one of these factors would start a chain reaction leading to lesions, then the other factors may combine to worsen the condition. With other words, peri‐implantitis is a general term dependent on a synergy of several factors, irrespective of the precise reason for first triggering off symptoms.
- 22 March 2012
- Published by Wiley in Clinical Implant Dentistry and Related Research
- Vol. 14 (2) , 170-183
The Peri‐Implantitis: Implant Surfaces, Microstructure, and Physicochemical Aspects
There are two ways of looking at secondary failures of osseointegration; one is to reflect on possible causes for the failure, the other focuses on the pathology per se. In the first case, background factors such as mechanical trauma (adverse loading) or inflammations/infections are being discussed as the cause of failure. Then peri‐implantitis is a term reserved for implant disturbance due to inflammation/infections only. However, irrespective of the original reason for the failure being adverse loading or inflammation/infection, the end result with bone resorption and inflammation may be very similar. Hence, in the present article, an alternative outlook has been chosen. Trigerring factors for peri‐implantitis are generally gathered under four categories: lesions of peri‐implant attachment, presence of aggressive bacteria, excessive mechanical stress, and corrosion. If only one of these factors would start a chain reaction leading to lesions, then the other factors may combine to worsen the condition. With other words, peri‐implantitis is a general term dependent on a synergy of several factors, irrespective of the precise reason for first triggering off symptoms.
- 1 December 2011
- Published by American Academy of Implant Dentistry in Journal of Oral Implantology
- Vol. 37 (6) , 681-690
Prevention of Hemorrhagic Complications After Dental Extractions Into Open Heart Surgery Patients Under Anticoagulant Therapy: The Use of Leukocyte- and Platelet-Rich Fibrin
Leukocyte- and platelet-rich fibrin (L-PRF) is a biomaterial commonly used in periodontology and implant dentistry to improve healing and tissue regeneration, particularly as filling material in alveolar sockets to regenerate bone for optimal dental implant placement. The objective of this work was to evaluate the use of L-PRF as a safe filling and hemostatic material after dental extractions (or avulsions) for the prevention of hemorrhagic complications in heart surgery patients without modification of the anticoagulant oral therapy. Fifty heart surgery patients under oral anticoagulant therapy who needed dental extractions were selected for the study. Patients were treated with L-PRF clots placed into 168 postextraction sockets without modification of anticoagulant therapy (mean international normalized ratio = 3.16 ± 0.39). Only 2 patients reported hemorrhagic complications (4%), all of which resolved a few hours after the surgery by compression and hemostatic topical agents. Ten patients (20%) showed mild bleeding, which spontaneously resolved or was resolved by minimal compression less than 2 hours after surgery. No case of delayed bleeding was reported. The remaining 38 patients (76%) showed an adequate hemostasis after the dental extractions. In all cases, no alveolitis or painful events were reported, soft tissue healing was quick, and wound closure was always complete at the time of suture removal one week after surgery. The proposed protocol is a reliable therapeutic option to avoid significant bleeding after dental extractions without the suspension of the continuous oral anticoagulant therapy in heart surgery patients. Other applications of the hemostatic and healing properties of L-PRF should be investigated in oral implantology.
- 1 December 2011
- Published by American Academy of Implant Dentistry in Journal of Oral Implantology
- Vol. 37 (6) , 681-690
Prevention of Hemorrhagic Complications After Dental Extractions Into Open Heart Surgery Patients Under Anticoagulant Therapy: The Use of Leukocyte- and Platelet-Rich Fibrin
Leukocyte- and platelet-rich fibrin (L-PRF) is a biomaterial commonly used in periodontology and implant dentistry to improve healing and tissue regeneration, particularly as filling material in alveolar sockets to regenerate bone for optimal dental implant placement. The objective of this work was to evaluate the use of L-PRF as a safe filling and hemostatic material after dental extractions (or avulsions) for the prevention of hemorrhagic complications in heart surgery patients without modification of the anticoagulant oral therapy. Fifty heart surgery patients under oral anticoagulant therapy who needed dental extractions were selected for the study. Patients were treated with L-PRF clots placed into 168 postextraction sockets without modification of anticoagulant therapy (mean international normalized ratio = 3.16 ± 0.39). Only 2 patients reported hemorrhagic complications (4%), all of which resolved a few hours after the surgery by compression and hemostatic topical agents. Ten patients (20%) showed mild bleeding, which spontaneously resolved or was resolved by minimal compression less than 2 hours after surgery. No case of delayed bleeding was reported. The remaining 38 patients (76%) showed an adequate hemostasis after the dental extractions. In all cases, no alveolitis or painful events were reported, soft tissue healing was quick, and wound closure was always complete at the time of suture removal one week after surgery. The proposed protocol is a reliable therapeutic option to avoid significant bleeding after dental extractions without the suspension of the continuous oral anticoagulant therapy in heart surgery patients. Other applications of the hemostatic and healing properties of L-PRF should be investigated in oral implantology.